The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is encoded by the protein kinase, DNA-activated, catalytic polypeptide (PRKDC) gene. DNA-PKcs plays a major role in nonhomologous end joining DNA repair, and it has been identified to be an important factor in tumor progression and metastasis. DNA-PKcs may have opposite effects in diseases, depending on the cell and tissue types. In this review, we discuss its role in various tumors. High levels of DNA-PKcs are directly associated with prognosis, neoplasm recurrence rates, and overall survival. Our results suggest that DNA-PKcs may serve as a therapeutic target for advanced malignancies.
KayserKDegenhardtFHolzapfelS, et al. Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes. Int J Cancer2018; 143: 2800–2813.
2.
ShrivastavMDe HaroLPNickoloffJA.Regulation of DNA double-strand break repair pathway choice. Cell Res2008; 18: 134–147.
3.
SteenSBGomelskyLSpeidelSL, et al. Initiation of V(D)J recombination in vivo: role of recombination signal sequences in formation of single and paired double-strand breaks. EMBO J1997; 16: 2656–2664.
4.
BradleyMOTaylorVI.DNA double-strand breaks induced in normal human cells during the repair of ultraviolet light damage. Proc Natl Acad Sci U S A1981;78:3619–3623.
5.
LiZOwonikokoTKSunSY, et al. c-Myc suppression of DNA double-strand break repair. Neoplasia2012; 14: 1190–1202.
6.
AbeTIshiaiMHosonoY, et al. KU70/80, DNA-PKcs, and Artemis are essential for the rapid induction of apoptosis after massive DSB formation. Cell Signal2008; 20: 1978–1985.
7.
YinXLiuMTianY, et al. Cryo-EM structure of human DNA-PK holoenzyme. Cell Res2017; 27: 1341–1350.
8.
HartleyKOGellDSmithGC, et al. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell1995; 82: 849–856.
9.
KloostermanWPTavakoli-YarakiMvan RoosmalenMJ, et al. Constitutional chromothripsis rearrangements involve clustered double-stranded DNA breaks and nonhomologous repair mechanisms. Cell Rep2012; 1: 648–655.
10.
ShrivastavMMillerCADe HaroLP, et al. DNA-PKcs and ATM co-regulate DNA double-strand break repair. DNA Repair2009; 8: 920–929.
11.
DavidsonDAmreinLPanasciL, et al. Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond. Front Pharmacol2013; 4: 5.
12.
TangXYuanFGuoK.Repair of radiation damage of U2OS osteosarcoma cells is related to DNA-dependent protein kinase catalytic subunit (DNA-PKcs) activity. Mol Cell Biochem2014; 390: 51–59.
13.
WuLZhangJWuH, et al. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600. Biochem Biophys Res Commun2015; 466: 547–553.
14.
SanFJSungPKleinH.Mechanism of eukaryotic homologous recombination. Annu Rev Biochem2008; 77: 229–257.
15.
BuntingSFNussenzweigA.End-joining, translocations and cancer. Nat Rev Cancer2013; 13: 443–454.
16.
ShrivastavMDe HaroLPNickoloffJA.Regulation of DNA double-strand break repair pathway choice. Cell Res2008; 18: 134–147.
17.
ChapmanJRTaylorMRBoultonSJ.Playing the end game: DNA double-strand break repair pathway choice. Mol Cell2012; 47: 497–510.
18.
LiWXieCYangZ, et al. Abnormal DNA-PKcs and Ku 70/80 expression may promote malignant pathological processes in gastric carcinoma. World J Gastroenterol2013; 19: 6894–6901.
19.
KotulaEBerthaultNAgrarioC, et al. DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion. Cell Cycle2015; 14: 1961–1972.
20.
GoodwinJFKothariVDrakeJM, et al. DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis. Cancer Cell2015; 28: 97–113.
21.
HsuFMZhangSChenBP.Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. Transl Cancer Res2012; 1: 22-34.
22.
AndersonCWCarterTH.The DNA-activated protein kinase: DNA-PK. Curr Top Microbiol Immunol1996; 217: 91–111.
23.
DietleinFThelenLJokicM, et al. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov2014; 4: 592–605.
24.
EvertMFrauMTomasiML, et al. Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value. Br J Cancer2013; 109: 2654–2664.
25.
MatsuokaTYashiroM.Rho/ROCK signaling in motility and metastasis of gastric cancer. World J Gastroenterol2014; 20: 13756–13766.
26.
ZhouYLeeJHJiangW, et al. Regulation of the DNA damage response by DNA-PKcs inhibitory phosphorylation of ATM. Mol Cell2017; 65: 91–104.
27.
PaullTT.Mechanisms of ATM activation. Annu Rev Biochem2015; 84: 711–738.
28.
GoodwinJFKnudsenKE.Beyond DNA repair: DNA-PK function in cancer. Cancer Discov2014; 4: 1126–1139.
29.
PolkinghornWRParkerJSLeeMX, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov2013; 3: 1245–1253.
30.
WongRHChangIHudakCS, et al. A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell2009; 136: 1056–1072.
31.
FengJParkJCronP, et al. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem2004; 279: 41189–41196.
32.
SunSChengSZhuY, et al. Identification of PRKDC (protein kinase, DNA-activated, catalytic polypeptide) as an essential gene for colorectal cancer (CRCs) cells. Gene2016; 584: 90–96.
33.
ZhengLLiangXLiS, et al. CHAF1A interacts with TCF4 to promote gastric carcinogenesis via upregulation of c-MYC and CCND1 expression. Ebiomedicine2018.
34.
ZhuWCaiMYTongZT, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymal transition. Gut2012; 61: 562–575.
35.
LiuJZhuMXiaX, et al. Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer. Oncotarget2016; 7: 85151–85162.
36.
AnJYangDYXuQZ, et al. DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein. Mol Cancer2008; 7: 32.
37.
ZhouZPatelMNgN, et al. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening. BMC Cancer2014; 14: 944.
38.
LuYZhangHLLiYZ, et al. [Clinicopathological significance of expressions of DNA dependent protein kinase catalytic subunit and P16 in colorectal carcinoma.] Zhonghua Yi Xue Za Zhi2008; 88: 2025–2029.
39.
HosoiYWatanabeTNakagawaK, et al. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol2004; 25: 461–468.
40.
DavidsonDCoulombeYMartinez-MarignacVL, et al. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs2012; 30: 1248–1256.
41.
SahlbergSHGustafssonASPendekantiPN, et al. The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol2014; 35: 3525–3534.
42.
RenWLiWWangD, et al. Combining multi-dimensional data to identify key genes and pathways in gastric cancer. Peerj2017; 5: e3385.
43.
WangFRWeiYCHanZJ, et al. Aberrant DNA-PKcs and ERGIC1 expression may be involved in initiation of gastric cancer. World J Gastroenterol2017; 23: 6119–6127.
44.
LeeHSChoeGParkKU, et al. Altered expression of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) during gastric carcinogenesis and its clinical implications on gastric cancer. Int J Oncol2007; 31: 859–866.
45.
ZhangYWenGMWuCA, et al. PRKDC is a prognostic marker for poor survival in gastric cancer patients and regulates DNA damage response. Pathol Res Pract2019; 215: 152509.
46.
CornellLMunckJMAlsinetC, et al. DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin Cancer Res2015; 21: 925–933.
47.
MaagJFisherOMLevert-MignonA, et al. Novel aberrations uncovered in Barrett’s esophagus and esophageal adenocarcinoma using whole transcriptome sequencing. Mol Cancer Res2017; 15: 1558–1569.
48.
TonotsukaNHosoiYMiyazakiS, et al. Heterogeneous expression of DNA-dependent protein kinase in esophageal cancer and normal epithelium. Int J Mol Med2006; 18: 441–447.
49.
NoguchiTShibataTFumotoS, et al. DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity. Ann Surg Oncol2002; 9: 1017–1022.
50.
LiNMaYMaL, et al. MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC. Cell Biol Int2017; 41: 622–629.
51.
ZhengBMaoJHLiXQ, et al. Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2alpha expression and cell proliferation. Sci Rep2016; 6: 29415.
52.
MoriNMatsumotoYOkumotoM, et al. Variations in Prkdc encoding the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and susceptibility to radiation-induced apoptosis and lymphomagenesis. Oncogene2001; 20: 3609–3619.
53.
WangXSzaboCQianC, et al. Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers. Cancer Res2008; 68: 971–975.
54.
ZhangYYangWKWenGM, et al. High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival. Mol Genet Genomic Med2019; 7: e908.
55.
McKean-CowdinRBarnholtz-SloanJInskipPD, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev2009; 18: 1118–1126.
56.
YanSSLiuLLiuZG, et al. [Expression and clinical significance of DNA-PKcs in nasopharyngeal carcinoma.] Ai Zheng2008; 27: 979–983.
